Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK plus NSCLC Leal, T., Wakelee, H., Infante, J., Blumenschein, G., Reckamp, K., Carter, C., Waqar, S., Gockerman, J., Lovly, C., Dukart, G., Harrow, K., Liang, C., Gibbons, J., Horn, L. ELSEVIER SCIENCE INC. 2016: S209–S210

View details for Web of Science ID 000427345100060